Skip to content

JBIO JBIO EPS (Basic)

EPS (Basic) at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$4.06+61.1%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$0.40+14.9%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$1.69-109%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$0.98+21.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$0.69+24.2%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's EPS (basic)?
JBIO (JBIO) reported EPS (basic) of -$0.57 in Q1 2026.
How has JBIO's EPS (basic) changed year-over-year?
JBIO's EPS (basic) increased by 95.3% year-over-year, from -$12.10 to -$0.57.
What is the long-term trend for JBIO's EPS (basic)?
Over 4 years (2021 to 2025), JBIO's EPS (basic) has grown at a -21.5% compound annual growth rate (CAGR), from -$35.62 to -$13.55.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.